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ANNOTATION
Antibody directed enzymes revive anti-cancer prodrugs concept
K.D. Bagshawe
Cancer Research Campaign Laboratories, Department ofMedical Oncology, Charing Cross Hospital, London W6 8RF, UK.
Within a few years of the beginnings of cancer chemotherapy
anticancer prodrugs were being synthesised. A series of azo
mustards was designed and produced by Ross and Warwick
(1955) at the Chester Beatty Research Institute so that under
in vivo conditions the azo link would be cleaved by enzymes
and agents with powerful alkylating activity would be
produced. Other latent compounds followed with a view to
activation by enzyme species thought to be present in greater
concentration in certain types of cancer than in normal
tissues (Connors, 1978; Carl et al., 1980). Unfortunately, a
favourable distribution of activating enzymes was not found
in human cancers and the prodrugs did not achieve the
selective toxicity that was sought.
Yet the approach was not fruitless. Cyclophosphamide
was developed as an agent that would be activated
enzymatically and although this proved to occur mainly in
the liver by the cytochrome P-450 system its place in cancer
chemotherapy needs no emphasis. More interesting in the
present context was the observation of Connors and others
(Connors & Melzack, 1971; Cobb et al., 1969) that one of
the compounds produced at the Chester Beatty (2,4-dinitro-
5-ethyleneminobenzamide), known as CB 1954, had a
profound effect on growth of the Walker rat carcinoma,
both in vivo and in culture, whilst it had little or no effect on
other cancers. This was surprising since it was a mono-
functional alkylating agent which should have been relatively
inert and the result implied that the Walker carcinoma cells
converted CB 1954 to a potent cytotoxic agent. Thus the
principle and potential benefits of drug activation at the site
of a cancer was established, although the active product was
not known. Recently, Roberts et al. (1986) have shown that
CB 1954 is converted in Walker carcinoma cells, presumably
by enzymatic action, to a difunctional agent resulting in
DNA-DNA interstrand links.
Whereas enzymes do not appear to be disposed in a
consistent and exploitable fashion in human tumours some
of their macromolecules viewed as antigenic determinants
have shown a more favourable distribution. Even though
tumour specific antigens have proved elusive, some antigens
have been found to be present in significantly greater
concentrations in tumours than in normal tissues of the host.
Such antigens when they are expressed on the cell membrane
or secreted into tumour extra-cellular fluid lend themselves
to the role of targets for antibodies. Monoclonal antibodies
armed with drugs, toxins or radioactive isotopes as cytotoxic
warheads are being studied intensively in many institutions.
Whilst some success has been claimed, there are various
obstacles to these approaches. One problem is heterogeneity
in the distribution of the antigens within tumour cell
populations so that even if an antibody-drug conjugate is
internalised by cells expressing the antigen a substantial
proportion of cells fail to express it and so escape. The
relationship between expression of these antigens and the
proliferative potential of cells has so far been little studied
and it is at least possible that some of the antigens are
markers of relatively differentiated cells within the tumour
population. Radiolabelled antibodies have the advantage
that they can irradiate cells from a site on the cell membrane
or from extra-cellular space through cross-fire effects. But
intravenously administered antibodies are slow to localise in
tumours and until that is achieved much of the radiation is
delivered somewhat indiscriminately. So it has proved
difficult to achieve the radiation dose necessary to eradicate
tumours without risking damage to normal renewal tissues.
Prodrugs require a favourable distribution of the
activating enzyme and the antibody approach needs some
form of amplification system. The limitations of enzyme
activated prodrugs and of antibody directed therapy could
find a common solution in the targeting of an enzyme to
tumours. Such targeting would localise the enzyme to sites
on the cell membrane or to extracellular sites around tumour
cells. A zinc metalloenzyme, carboxypeptidase G2 which was
isolated from a Pseudomonas strain and catalyses the
hydrolytic cleavage of reduced and non-reduced folates to
pteroates and L glutamate, has been linked to a monoclonal
antibody raised to human chorionic gonadotrophin
(Bagshawe, 1983, 1985). JAR line choriocarcinoma cells lost
viability when exposed to the antibody-enzyme conjugate
(Searle et al., 1986). Further studies with a radioiodine label
on the enzyme have shown that the conjugate is taken up
selectively by a choriocarcinoma xenograft in nude mice and
that the conjugate reduced the serum folate level (Melton et
al., 1987). Similarly when the enzyme was conjugated to an
antibody directed at carcinoembryonic antigen the conjugate
localised in a colonic adenocarcinoma xenograft.
Thus the enzyme activated prodrug concept need no
longer depend on the fortuitous distribution of an enzyme. It
should be possible to direct into tumour targets an enzyme
that matches a particular prodrug. As with intact antibody,
an antibody-enzyme complex only achieves the most
favourable tumour to non-tumour distribution ratio some
days after i.v. injection but by this time it has been largely
cleared from the blood and normal tissues. Administration
of a prodrug at this time should result in generation of the
active drug selectively at tumour sites.
Enzymes chosen for such a role can be non-mammalian in
origin and thus lack a human analogue. Ideally, there would
be no comparable enzyme in the intestinal flora although the
importance or otherwise of this would depend on the nature
of the prodrug and whether it was secreted into the gastro-
intestinal tract. It will be necessary to ensure that the
enzymes selected can be conjugated to antibodies and remain
stable and active in the extra-cellular fluid compartment of
tumours for relatively long periods. Our initial studies have
used an antibody chemically conjugated to the enzyme but if
early studies were successful a long term objective would be
genetically engineered molecules with the antigen binding
sites of an antibody and an enzyme substitute for the Fc
component (Neuberger et al., 1984).
The requirements for a prodrug are that it should be a
compound of low toxicity that can be converted to a highly
active cytotoxic substance only by the action of the chosen
enzyme. The active product is likely to be a small molecule
and therefore highly diffusible through the tumour. A short
half life perhaps measured in seconds rather than minutes,
would contribute to the avoidance of toxic effects on normal
cell renewal tissues.
One fundamental question is whether delivery of
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alkylating agents or other cytotoxic drugs in this way can
overcome the problems of drug resistance. This may depend
on the ability to sustain a high local concentration of
cytotoxic molecules for a sufficiently prolonged period to kill
all clonogenic cells at each tumour site.
There is also the problem of host antibody response to
foreign protein which applies to all antibody based targeting
and which may be aggravated by linkage to an enzyme of
non-mammalian origin. Clearly, the introduction of foreign
protein into tumours will need to be complete before the
host antibody response takes effect.
It has been shown that the anti-antibody response can be
deferred by using ultracentrifuged antibody preparations to
eliminate aggregates and to combine this with cyclosporin
administration (Ledermann et al., 1987). Antibodies could be
switched in terms of antigenic targets and species of origin
and alternative enzymes are likely to be available but there is
no certainty that host responses to one species of immuno-
globulin will not cross react with immunoglobulins from
another. Human antibodies or humanised foreign antibodies
may provide a solution but the fact that host antibodies may
be predominantly antiidiotypic (Jaffers et al., 1986) suggests
that host immune response will remain a potentially
formidable obstacle to repeated treatments unless better ways
of inhibiting it are found.
These problems of drug resistance and host response
inevitably influence the way in which antibody directed
enzyme therapy (ADEPT) might be used. Essentially it will
be a two stage process. In the first stage the objective would
be to deliver the antibody-enzyme conjugate in an amount
that will achieve and retain the highest concentration of
enzyme at tumour sites. The percentage of administered
antibody that localises in xenografted tumours is often of the
order of 3-5% per gram of tumour but higher values are
obtained with some antibodies. However, the percentage
retention in the human may be much lower. The highest
tumour/non-tumour ratios for antibody localisation are
achieved 3-7 days post administration but during this time
the absolute concentration of antibody in tumour tissue falls
from its peak value. The optimum interval between
administration of the antibody-enzyme conjugate and the
second stage of administering the prodrug will probably be a
compromise between peak tumour concentration of enzyme
and the best distribution ratio between tumour and normal
tissues.
The first matching antibody-enzyme-prodrug combination
has been produced by collaboration between the Cancer
Research Campaign funded groups at Charing Cross,
CAMR (Porton), and the Institute of Cancer Research and
is now undergoing laboratory evaluation. The potential
multiplicity of non-mammalian enzymes and prodrugs
suggests that targeted enzyme chemotherapy is a large new
area that we can now begin to explore. In the short term at
least, the range of cancers that could be treated would be
limited by the range of suitable antibodies. If early
experience proves encouraging the drive to find more
antibodies with specificity for human cancers will receive
added impetus.
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